Cartesian Therapeutics to Participate in Upcoming Investor Conferences

About this update from Cartesian Therapeutics, Inc.

FREDERICK, Md., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September: Live webcasts of the fireside chats and presentation are expected to be accessible in the Events section of the Company’s website at  www.cartesiantherapeutics.com , where an archived replay of the events will also be available for a limited time. About Cartesian Therapeutics Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X , formerly known as Twitter. Investor Contact Megan LeDuc Associate Director, Investor Relations [email protected] Media Contact David Rosen Argot Partners [email protected]

View stock analysis, news, and events for Cartesian Therapeutics, Inc.